- Home
- GBR vs OGEN Comparison
GBR vs OGEN Comparison
Compare GBR & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBR
- OGEN
- Stock Information
- Founded
- GBR 1978
- OGEN 1996
- Country
- GBR United States
- OGEN United States
- Employees
- GBR N/A
- OGEN N/A
- Industry
- GBR Oil & Gas Production
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- GBR Energy
- OGEN Health Care
- Exchange
- GBR Nasdaq
- OGEN Nasdaq
- Market Cap
- GBR 4.5M
- OGEN 4.6M
- IPO Year
- GBR N/A
- OGEN N/A
- Fundamental
- Price
- GBR $0.86
- OGEN $0.17
- Analyst Decision
- GBR
- OGEN
- Analyst Count
- GBR 0
- OGEN 0
- Target Price
- GBR N/A
- OGEN N/A
- AVG Volume (30 Days)
- GBR 35.8K
- OGEN 232.4K
- Earning Date
- GBR 05-20-2025
- OGEN 05-19-2025
- Dividend Yield
- GBR N/A
- OGEN N/A
- EPS Growth
- GBR N/A
- OGEN N/A
- EPS
- GBR N/A
- OGEN N/A
- Revenue
- GBR $146,000.00
- OGEN N/A
- Revenue This Year
- GBR N/A
- OGEN N/A
- Revenue Next Year
- GBR N/A
- OGEN N/A
- P/E Ratio
- GBR N/A
- OGEN N/A
- Revenue Growth
- GBR N/A
- OGEN N/A
- 52 Week Low
- GBR $0.67
- OGEN $0.16
- 52 Week High
- GBR $1.82
- OGEN $3.43
- Technical
- Relative Strength Index (RSI)
- GBR 61.52
- OGEN 38.28
- Support Level
- GBR $0.67
- OGEN $0.16
- Resistance Level
- GBR $0.87
- OGEN $0.19
- Average True Range (ATR)
- GBR 0.06
- OGEN 0.01
- MACD
- GBR 0.02
- OGEN 0.00
- Stochastic Oscillator
- GBR 90.81
- OGEN 17.20
About GBR New Concept Energy Inc
New Concept Energy Inc is a United States-based company engaged in Real Estate Operations. It intends to continue to operate and or sell its West Virginia property. It provides advisory and management services for an independent West Virginia oil and gas company. The Company seeks to establish or acquire new business operations. It operates in one segment, which is real estate rental.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.